Route de la Corniche 5, Epalinges, Switzerland
Ariceum International AG is the Swiss affiliate of Ariceum Therapeutics GmbH, a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of hard-to-treat cancers. Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan.
We are specialized in processes optimization and validation, GMP and ISO compliance aspects, quality systems, risk analysis, CE marking, equipment qualification, project management, etc.
At Navignostics we characterize tumors using spatial single-cell proteomics. We use unique capabilities to identify a cancer treatment that will optimally fight a tumor. We accelerate cancer drug development by providing key insights into drug mechanisms and tumor features to pharma companies.
